Oxygen shares soar following positive Levosimendan data


Oxygen Biotherapeutics' (OXBT) Levosimendan product significantly improves post-operative kidney function in patients who have undergone surgery of the mitral valve in the heart, evidence from a study published in the Journal of Cardiothoracic & Vascular Anesthesia shows.

Oxygen Biotherapeutics expects to begin a Phase III trial of Levosimendan in Q3 for patients undergoing coronary artery by-pass and or mitral valve surgery.

Shares +22%. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs